. Time course of specific [11C]PIB and [18F]FDDNP binding: paired studies in patients with Alzheimer's disease, mild cognitive impairment and healthy controls. Human Amyloid Imaging 2011 Meeting Abstracts. 2011 Jan 15;


Background: [11C]PIB and [18F]FDDNP are PET tracers for in vivo assessment of neuropathological characteristics underlying Alzheimer's disease (AD). It has been shown that [11C]PIB has high diagnostic sensitivity for detecting AD. Follow-up studies, however, have shown inconsistent results with either no or only modest changes of [11C] PIB binding over time. [18F]FDDNP also discriminates between AD and healthy controls, but has a 9-fold lower specific signal compared with [11C]PIB. It has been suggested, however, that [18F]FDDNP reflects presence of neurofibrillary tangles, which are strongly related to cognition and disease progression. In the present longitudinal study, changes in both [11C]PIB and [18F]FDDNP were investigated in patients with AD and mild cognitive impairment (MCI), and in healthy controls (HC).

Methods: Repeated, paired, dynamic 90 minute, [11C]PIB and [18F]FDDNP PET scans were performed in 11 controls, 12 MCI patients and 7 AD patients. The mean interval between baseline and follow-up scans was 2.5 years (range: 2.0-4.0 years). For both tracers, parametric images of binding potential (BPND) were generated using a basis function implementation of the simplified reference tissue model. Changes in global cortical BPND were evaluated using paired t-tests.

Results: A significant increase (m}sd baseline: 0.404}0.412, follow-up: 0.440}0.408) in global [11C]PIB BPND (t(28) = 2.104, p = 0.044) was found. This increase was most prominent in healthy controls (m}sd baseline: 0.123}0.272, follow-up: 0.148}0.288, t(10) = 2.242, p = 0.049) and MCI patients (m}sd baseline: 0.389}0.393, follow-up: 0.462}0.391, t(10) = 2.165, p = 0.056). No change was found for AD patients (m}sd baseline: 0.868}0.095, follow-up: 0.863}0.129, t(6) = -0.961, p = 0.906). For [18F]FDDNP, no longitudinal changes in global BPND were found (m}sd baseline: 0.058}0.034, follow-up: 0.060}0.035, t(29) = 0.303, p = 0.764).

Conclusions: A significant increase in [11C]PIB binding over time was observed, especially in controls and MCI patients. These results suggest that amyloid deposition predominantly occurs during preclinical stages of AD, and reaches a plateau once progression to AD is clinically established.


Please login to recommend the paper.


Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Miami: HAI Amyloid Imaging Conference Abstracts